JanÂ-ne BackÂ-man

List of Publications by Year
in descending order

187	13,853	14655 66	23533 111
papers	citations	h-index	g-index

188	188	188	8922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Translational aspects of cytochrome P450â€mediated drugâ€“drug interactions: A case study with clopidogrel. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 48-59.	2.5	3
2	Pharmacogenomics of celiprolol â€“ evidence for a role of Pâ€glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clinical and Translational Science, 2022, 15, 409-421.	3.1	4
3	Systemic hypertonic saline enhances glymphatic spinal cord delivery of lumbar intrathecal morphine. Journal of Controlled Release, 2022, 344, 214-224.	9.9	9
4	Healthcare costs and mortality associated with serious fluoroquinoloneâ€related adverse reactions. Pharmacology Research and Perspectives, 2022, 10, e00931.	2.4	4
5	Medicines, environment and clinical pharmacology. Basic and Clinical Pharmacology and Toxicology, 2022, 131, 149-152.	2.5	2
6	Genomewide Association Study of Simvastatin Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2022, 112, 676-686.	4.7	14
7	Relationship of Edoxaban Plasma Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis. Journal of Clinical Pharmacology, 2021, 61, 522-530.	2.0	2
8	Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. European Journal of Clinical Pharmacology, 2021, 77, 643-650.	1.9	11
9	Health service use and costs associated with fluoroquinoloneâ€related tendon injuries. Pharmacology Research and Perspectives, 2021, 9, e00796.	2.4	7
10	An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes â€“ application to establishing CYP2C8 inhibitor selectivity. European Journal of Pharmaceutical Sciences, 2021, 162, 105810.	4.0	7
11	Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. Clinical Pharmacology and Therapeutics, 2021, 110, 1622-1632.	4.7	20
12	Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. Anesthesia and Analgesia, 2021, 133, 423-434.	2.2	1
13	Itraconazole Increases Ibrutinib Exposure 10â€Fold and Reduces Interindividual Variationâ€”A Potentially Beneficial Drugâ€Drug Interaction. Clinical and Translational Science, 2020, 13, 345-351.	3.1	25
14	Comparison of LC-MS/MS and chemiluminescent immunoassays for immunosuppressive drugs reveals organ dependent variation in blood cyclosporine a concentrations. Clinica Chimica Acta, 2020, 508, 22-27.	1.1	7
15	Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clinical and Translational Science, 2020, 13, 1236-1243.	3.1	20
16	UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokineticsâ€”A Comprehensive Pharmacogenomic Study. Clinical Pharmacology and Therapeutics, 2020, 108, 885-895.	4.7	11
17	Effect of Highâ€Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Longâ€lasting Inhibition of CYP2C19. Clinical Pharmacology and Therapeutics, 2020, 108, 1254-1264.	4.7	13
18	CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. Clinical Pharmacology and Therapeutics, 2019, 105, 448-457.	4.7	22

#	Article	IF	Citations
19	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 2013-2019.	2.4	21
20	Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs. Journal of Controlled Release, 2019, 304, 29-38.	9.9	73
21	Enantiospecific Pharmacogenomics of Fluvastatin. Clinical Pharmacology and Therapeutics, 2019, 106, 668-680.	4.7	26
22	Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. PLoS ONE, 2019, 14, e0216029.	2.5	23
23	Clinical Studies on Drugâ€“Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clinical Pharmacology and Therapeutics, 2019, 105, 1345-1361.	4.7	107
24	Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. Drug Metabolism and Disposition, 2019, 47, 436-443.	3.3	7
25	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Drug Metabolism and Disposition, 2019, 47, 377-385.	3.3	15
26	Response to â€œInteraction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?â€• Clinical Pharmacology and Therapeutics, 2019, 105, 322-322.	4.7	1
27	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2019, 105, 219-228.	4.7	51
28	Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. International Journal of Pharmaceutics, 2018, 544, 121-128.	5.2	9
29	Implications of intercorrelation between hepatic CYP3A4â€CYP2C8 enzymes for the evaluation of drugâ€“drug interactions: a case study with repaglinide. British Journal of Clinical Pharmacology, 2018, 84, 972-986.	2.4	19
30	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 341-345.	2.5	12
31	Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2018, 104, 158-168.	4.7	19
32	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8â€Mediated Metabolism of Montelukast in Humans. Clinical Pharmacology and Therapeutics, 2018, 104, 495-504.	4.7	14
33	Prevention of chemotherapyâ€induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 417-432.	7.3	48
34	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions^{â€‰}. Drug Metabolism and Disposition, 2018, 46, 141-150.	3.3	22
35	Voriconazole greatly increases the exposure to oral buprenorphine. European Journal of Clinical Pharmacology, 2018, 74, 1615-1622.	1.9	12
36	Cytochrome P450 in Pharmacogenetics: An Update. Advances in Pharmacology, 2018, 83, 3-32.	2.0	113

#	Article	IF	Citations
37	In Vitro Screening of Six Protein Kinase Inhibitors for Timeâ€Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drugâ€“Drug Interactions. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 739-748.	2.5	14
38	Implications of inter-correlation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide and gemfibrozil. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-13-2.	0.0	0
39	Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis. Clinical Science, 2017, 131, 747-758.	4.3	12
40	UDP-glucuronosyltransferase catalyzed drug bioactivation: Mechanisms and potential for clinically significant drug-drug interactions. Drug Metabolism and Pharmacokinetics, 2017, 32, S20.	2.2	0
41	Pilot Study of Propofol-induced Slow Waves as a Pharmacologic Test for Brain Dysfunction after Brain Injury. Anesthesiology, 2017, 126, 94-103.	2.5	12
42	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 83-95.	3.3	30
43	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Drug Metabolism and Disposition, 2016, 44, 1364-1371.	3.3	30
44	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Pharmacology Research and Perspectives, 2016, 4, e00271.	2.4	9
45	Using Hilbert-Huang Transform to assess EEG slow wave activity during anesthesia in post-cardiac arrest patients. , 2016, 2016, 1850-1853.		2
46	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. European Journal of Clinical Pharmacology, 2016, 72, 1363-1371.	1.9	15
47	VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13144-13149.	7.1	98
48	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60â€yearâ€old Caucasian woman with ovarian carcinoma. British Journal of Clinical Pharmacology, 2016, 81, 313-315.	2.4	20
49	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews, 2016, 68, 168-241.	16.0	175
50	Intravenous Lipid Emulsion Given to Volunteers does not Affect Symptoms of Lidocaine Brain Toxicity. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 378-383.	2.5	43
51	Effect of carboxylesterase 1 c.428Gâ€‰>â€‰A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. British Journal of Clinical Pharmacology, 2015, 80, 1131-1138.	2.4	35
52	Drugâ€Related Inadvertent Deaths in a University Hospital â€“ A Declining Trend. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 421-426.	2.5	22
53	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenetics and Genomics, 2015, 25, 382-387.	1.5	122
54	Targeting matrix metalloproteinases with intravenous doxycycline in severe sepsis â€“ A randomised placebo-controlled pilot trial. Pharmacological Research, 2015, 99, 44-51.	7.1	10

#	Article	IF	Citations
55	Effect of grapefruit juice on the bioactivation of prasugrel. British Journal of Clinical Pharmacology, 2015, 80, 139-145.	2.4	13
56	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology, 2015, 71, 321-327.	1.9	30
57	Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. European Journal of Clinical Pharmacology, 2015, 71, 441-447.	1.9	69
58	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clinical Pharmacology and Therapeutics, 2015, 97, 650-658.	4.7	70
59	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. Drug Metabolism and Disposition, 2015, 43, 1655-1660.	3.3	25
60	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2014, 96, 498-507.	4.7	124
61	Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. Drug Metabolism and Disposition, 2014, 42, 2068-2076.	3.3	9
62	Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy. Annals of Surgery, 2014, 259, 26-31.	4.2	42
63	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2014, 95, 307-313.	4.7	49
64	In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors. Drug Metabolism and Disposition, 2014, 42, 1202-1209.	3.3	56
65	Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. Drug Metabolism and Disposition, 2013, 41, 50-59.	3.3	57
66	Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite. Clinical Pharmacology and Therapeutics, 2013, 94, 383-393.	4.7	28
67	Intravenous Lipid Emulsion Entraps Amitriptyline into Plasma and Can Lower its Brain Concentration â€“ An Experimental Intoxication Study in Pigs. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 193-200.	2.5	45
68	A Time-to-Event Model for Acute Rejections in Paediatric Renal Transplant Recipients Treated with Ciclosporin A. British Journal of Clinical Pharmacology, 2013, 76, n/a-n/a.	2.4	14
69	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. British Journal of Clinical Pharmacology, 2013, 75, 1488-1496.	2.4	32
70	SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenetics and Genomics, 2013, 23, 19-24.	1.5	36
71	Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin. Journal of Clinical Pharmacology, 2012, 52, 347-360.	2.0	16
72	Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses. Clinical Pharmacology and Therapeutics, 2012, 91, 846-855.	4.7	36

#	Article	IF	Citations
73	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences, 2012, 33, 312-322.	8.7	85
74	Potent mechanismâ€based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. British Journal of Pharmacology, 2012, 165, 2787-2798.	5.4	74
75	Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. Clinical Pharmacology and Therapeutics, 2012, 92, 68-71.	4.7	64
76	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. European Journal of Clinical Pharmacology, 2012, 68, 681-688.	1.9	13
77	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. British Journal of Clinical Pharmacology, 2012, 73, 257-267.	2.4	39
78	Gender, but not CYP7A1 or SLCO1B1 Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 245-252.	2.5	37
79	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. Journal of Clinical Pharmacology, 2011, 51, 359-367.	2.0	54
80	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. Clinical Pharmacology and Therapeutics, 2011, 89, 579-586.	4.7	50
81	The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. European Journal of Clinical Pharmacology, 2011, 67, 151-155.	1.9	12
82	No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. European Journal of Clinical Pharmacology, 2011, 67, 1159-1167.	1.9	6
83	Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. Drug Metabolism and Disposition, 2011, 39, 1977-1986.	3.3	58
84	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. Drug Metabolism and Disposition, 2011, 39, 904-911.	3.3	42
85	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. Clinical Pharmacology and Therapeutics, 2010, 88, 223-230.	4.7	54
86	Longâ€Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism. Journal of Clinical Pharmacology, 2010, 50, 581-597.	2.0	25
87	Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1107-1114.	5.6	221
88	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. British Journal of Clinical Pharmacology, 2009, 68, 207-213.	2.4	52
89	CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. Drug Metabolism and Disposition, 2009, 37, 2359-2366.	3.3	49
90	Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenetics and Genomics, 2009, 19, 447-457.	1.5	56

#	Article	IF	Citations
91	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. European Journal of Clinical Pharmacology, 2008, 64, 17-24.	1.9	42
92	Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. European Journal of Clinical Pharmacology, 2008, 64, 511-519.	1.9	16
93	In vitro Inhibition of CYP1A2 by Model Inhibitors, Antiâ€inflammatory Analgesics and Female Sex Steroids: Predictability of in vivo Interactions. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 157-165.	2.5	41
94	The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. Clinical Pharmacology and Therapeutics, 2008, 84, 403-411.	4.7	79
95	Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clinical Pharmacology and Therapeutics, 2008, 84, 488-496.	4.7	71
96	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics, 2008, 47, 463-474.	3.5	177
97	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics Journal, 2008, 8, 268-277.	2.0	59
98	Trimethoprim and the CYP2C8[*]3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. Drug Metabolism and Disposition, 2008, 36, 73-80.	3.3	110
99	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenetics and Genomics, 2008, 18, 77-90.	1.5	71
100	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and Genomics, 2008, 18, 937-942.	1.5	59
101	Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolamâ€"Probes of CYP2C9, CYP1A2, and CYP3A4. Clinical Pharmacology and Therapeutics, 2007, 81, 833-839.	4.7	84
102	Developmental pharmacokinetics of ciclosporin â€“ a population pharmacokinetic study in paediatric renal transplant candidates. British Journal of Clinical Pharmacology, 2007, 64, 772-784.	2.4	54
103	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. European Journal of Clinical Pharmacology, 2007, 63, 463-469.	1.9	34
104	Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. European Journal of Clinical Pharmacology, 2007, 63, 829-836.	1.9	13
105	Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thrombosis and Haemostasis, 2006, 95, 253-259.	3.4	110
106	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and Genomics, 2006, 16, 801-808.	1.5	96
107	Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitors in vitro. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 79-85.	2.5	100
108	Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 44-51.	2.5	123

#	Article	IF	Citations
109	Effect of rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology, 2006, 61, 70-78.	2.4	75
110	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. British Journal of Clinical Pharmacology, 2006, 62, 345-357.	2.4	62
111	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clinical Pharmacology and Therapeutics, 2006, 79, 231-242.	4.7	44
112	Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics, 2006, 80, 565-581.	4.7	705
113	Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. European Journal of Clinical Pharmacology, 2006, 62, 217-223.	1.9	32
114	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. European Journal of Clinical Pharmacology, 2006, 62, 409-415.	1.9	106
115	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. European Journal of Clinical Pharmacology, 2006, 62, 451-461.	1.9	59
116	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. European Journal of Clinical Pharmacology, 2006, 62, 463-472.	1.9	79
117	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. European Journal of Clinical Pharmacology, 2006, 62, 503-509.	1.9	30
118	The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. European Journal of Clinical Pharmacology, 2006, 62, 645-651.	1.9	24
119	Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. Drug Metabolism and Disposition, 2006, 34, 2091-2096.	3.3	37
120	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics, 2005, 15, 303-309.	1.5	112
121	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clinical Pharmacology and Therapeutics, 2005, 77, 404-414.	4.7	99
122	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics, 2005, 77, 468-478.	4.7	320
123	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical Pharmacology and Therapeutics, 2005, 78, 154-167.	4.7	132
124	Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clinical Pharmacology and Therapeutics, 2005, 78, 400-411.	4.7	87
125	Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2005, 78, 388-399.	4.7	180
126	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2005, 59, 433-439.	2.4	40

#	Article	IF	Citations
127	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. British Journal of Clinical Pharmacology, 2005, 60, 208-217.	2.4	36
128	Comparison of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) as Inhibitors of Cytochrome P450 2C8. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 104-108.	2.5	34
129	Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 249-256.	2.5	149
130	Effect of Itraconazole on the Pharmacokinetics of Atenolol. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 395-398.	2.5	11
131	Cyclosporine A monitoring ? how to account for twice and three times daily dosing. Pediatric Nephrology, 2005, 20, 591-596.	1.7	6
132	Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. British Journal of Clinical Pharmacology, 2004, 58, 390-396.	2.4	35
133	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. British Journal of Clinical Pharmacology, 2004, 57, 441-447.	2.4	81
134	Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. British Journal of Clinical Pharmacology, 2004, 57, 349-353.	2.4	84
135	Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction*1. Clinical Pharmacology and Therapeutics, 2004, 75, 331-341.	4.7	98
136	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics, 2004, 76, 239-249.	4.7	80
137	Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2?mediated presystemic metabolism. Clinical Pharmacology and Therapeutics, 2004, 76, 598-606.	4.7	130
138	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
139	Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clinical Pharmacology and Therapeutics, 2003, 73, 192-198.	4.7	126
140	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46, 347-351.	6.3	269
141	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, 46, 1319-1323.	6.3	167
142	Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics, 2003, 73, 538-544.	4.7	170
143	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 25-31.	4.7	20
144	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 380-387.	4.7	154

#	Article	IF	Citations
145	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. British Journal of Clinical Pharmacology, 2003, 56, 427-432.	2.4	40
146	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 2003, 57, 181-187.	2.4	66
147	Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics, 2003, 42, 819-850.	3.5	591
148	Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes. Drug Metabolism and Disposition, 2002, 30, 1352-1356.	3.3	174
149	Effect of Albumin and Cytosol on Enzyme Kinetics of Tolbutamide Hydroxylation and on Inhibition of CYP2C9 by Gemfibrozil in Human Liver Microsomes. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 43-49.	2.5	19
150	Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively. Drug Metabolism and Disposition, 2002, 30, 631-635.	3.3	141
151	Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by Î²-Glucuronidase. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 223-228.	2.5	51
152	Expression of active human Î²-glucuronidase in Sf9 cells infected with recombinant baculovirus. Life Sciences, 2002, 71, 1547-1557.	4.3	5
153	Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. European Journal of Clinical Pharmacology, 2002, 57, 799-804.	1.9	143
154	Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics, 2002, 72, 685-691.	4.7	296
155	Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. European Journal of Clinical Pharmacology, 2001, 57, 37-42.	1.9	37
156	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. British Journal of Clinical Pharmacology, 2001, 52, 399-407.	2.4	18
157	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British Journal of Clinical Pharmacology, 2001, 52, 547-553.	2.4	131
158	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology and Therapeutics, 2001, 69, 194-200.	4.7	59
159	Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clinical Pharmacology and Therapeutics, 2001, 69, 340-345.	4.7	174
160	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clinical Pharmacology and Therapeutics, 2001, 69, 400-406.	4.7	104
161	Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. Journal of Antimicrobial Chemotherapy, 2001, 48, 881-885.	3.0	69
162	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. British Journal of Clinical Pharmacology, 2000, 50, 591-595.	2.4	46

#	Article	IF	Citations
163	Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiologica Scandinavica, 2000, 44, 69-74.	1.6	66
164	Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clinical Pharmacology and Therapeutics, 2000, 67, 215-221.	4.7	45
165	Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clinical Pharmacology and Therapeutics, 2000, 67, 382-390.	4.7	42
166	Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clinical Pharmacology and Therapeutics, 2000, 68, 122-129.	4.7	235
167	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clinical Pharmacology and Therapeutics, 2000, 68, 487-494.	4.7	105
168	Rifampin decreases the plasma concentrations and effects of repaglinide. Clinical Pharmacology and Therapeutics, 2000, 68, 495-500.	4.7	91
169	Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clinical Pharmacology and Therapeutics, 2000, 68, 592-597.	4.7	132
170	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. European Journal of Clinical Pharmacology, 2000, 56, 225-229.	1.9	111
171	Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. European Journal of Clinical Pharmacology, 2000, 56, 411-415.	1.9	85
172	Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. Journal of Antimicrobial Chemotherapy, 2000, 45, 701-704.	3.0	66
173	Midazolam Î±â€Hydroxylation by Human Liver Microsomes in vitro: Inhibition by Calcium Channel Blockers, Itraconazole and Ketoconazole. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 157-161.	0.0	56
174	Fluvoxamine is a More Potent Inhibitor of Lidocaine Metabolism than Ketoconazole and Erythromycin in vitro. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 201-205.	0.0	32
175	Itraconazole Decreases the Clearance and Enhances the Effects of Intravenously Administered Methylprednisolone in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 29-32.	0.0	53
176	Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clinical Pharmacology and Therapeutics, 1999, 66, 448-453.	4.7	59
177	Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue. The Histochemical Journal, 1999, 31, 645-649.	0.6	3
178	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam*1. Clinical Pharmacology and Therapeutics, 1999, 66, 401-407.	4.7	33
179	Grapefruit juice substantially increases plasma concentrations of buspirone*. Clinical Pharmacology and Therapeutics, 1998, 64, 655-660.	4.7	119
180	Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis and Rheumatism, 1998, 41, 122-129.	6.7	191

#	Article	IF	Citations
181	The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. European Journal of Clinical Pharmacology, 1998, 54, 53-58.	1.9	246
182	The Role of Î²-Glucuronidase in Drug Disposition and Drug Targeting in Humans. Clinical Pharmacokinetics, 1997, 33, 18-31.	3.5	153
183	Triazolam is ineffective in patients taking rifampin. Clinical Pharmacology and Therapeutics, 1997, 61, 8-14.	4.7	96
184	Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin. Epilepsia, 1996, 37, 253-257.	5.1	133
185	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical Pharmacology and Therapeutics, 1996, 59, 7-13.	4.7	219
186	Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 1994, 55, 481-485.	4.7	386
187	Dose of midazolam should be reduced during diltiazem and verapamil treatments.. British Journal of Clinical Pharmacology, 1994, 37, 221-225.	2.4	164